{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-002078","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.224870+00:00","generated_at":"2026-06-20T18:00:32.540684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aziyo Biologics reports record annual net sales of ~$49M, Q4 up 15-17% YoY","bullets":["Preliminary Q4 2022 net sales of ~$12.5-12.7M, up 15-17% vs Q4 2021.","Full year 2022 record net sales of ~$49.0-49.2M, up 3-4% YoY; up ~15-16% excluding $4.9M discontinued product.","SimpliDerm and CanGaroo combined Q4 net sales expected to grow ~30% vs Q4 2021.","Company raised $15.2M in gross proceeds from recent financings; awaits FDA clearance for CanGaroo RM.","CEO cites strong team performance; full Q4 and FY results expected in early March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-002078","json":"https://secwatch.observer/filing/0001104659-23-002078.json","markdown":"https://secwatch.observer/filing/0001104659-23-002078.md","text":"https://secwatch.observer/filing/0001104659-23-002078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/tm232674d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:00:32.540684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bc05bac941c0aaa7b5e1c1859500022886c2056","claim":"ELUTIA INC. reported fourth quarter ended December 31, 2022 results: revenue approximately $12.5-$12.7 million.","evidence_excerpt":"Anticipate fourth quarter 2022 net sales of approximately $12.5-$12.7 million, an increase of 15%-17% compared to the same prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"approximately $12.5-$12.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"d009a500211090d6ea9fb9d200cc24b8e9b67af2","claim":"ELUTIA INC. reported full year ended December 31, 2022 results: revenue approximately $49.0-$49.2 million.","evidence_excerpt":"Anticipate full year 2022 record net sales of approximately $49.0-$49.2 million, an increase of 3%-4% compared to the prior year and , after excluding 2021 sales of a discontinued product of $4.9 million, an increase of approximately 15%-16%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923002078/0001104659-23-002078-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"approximately $49.0-$49.2 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}